Contamination of the external surfaces of drug vials with antineoplastic drugs has been reported in some countries. However, this has rarely been reported in Japan. The aim of this study was to investigate the external contamination level of doxorubicin vials in Japan. The external surfaces of 57 vials of six products containing doxorubicin were wiped with a non-woven fabric, and the contamination levels of doxorubicin were analysed by high-performance liquid chromatography combined with fluorescence detection; doxorubicin was confirmed by high performance liquid chromatography combined with quadrupole time-of-flight mass spectrometry. The surfaces of 28 of 57 vials were contaminated with doxorubicin. The maximum contamination level was 12.3 ng per vial. The external surfaces of some doxorubicin product vials produced by Japanese pharmaceutical companies were contaminated with doxorubicin.
Introduction
Although antineoplastic drugs are prescribed to treat cancer, they are themselves mutagenic, teratogenic and carcinogenic. In fact, many are classi ed as either Group 1, carcinogenic to humans, or Group 2, probably In general, antineoplastic drugs are administered by transfusion; therefore, medical staff is exposed through drug preparation, administration and disposal. In fact, it has been reported since 1970s that occupational exposures to antineoplastic drugs may affect the health of medical staff. Furthermore, several studies have found that the external surfaces of new drug vials were contaminated with antineoplastic drugs. [2] [3] [4] [5] [6] [7] However, the similar contamination has also been reported in Japan. [8] [9] In addition, contamination levels dif-＊ 3-69, 1-chome, Nakamichi, Higashinari-ku, Osaka 537-0025, Japan While doxorubicin (DXR) has been used to treat many cancers because of its broad antitumor spectrum as monotherapy and multidrug therapy, it is one of the most likely sources of occupational exposures.
We investigated the contamination level on the external surfaces of DXR vials in Japan to acquire more knowledge about the external contamination of vials in Japan. In this paper, we report the external contamination level of DXR vials on account of the detection for the rst time in Japan contrary to the past report.
Materials and Methods

Pharmaceutical products
We investigated six parenteral injection products containing 10 or 50 mg DXR hydrochloride (DXR HCl) that were commercially available in Japan. The 50 mg DXR vials were larger than the 10 mg vials. The 50 mg DXR vials were packaged in cardboard boxes individually, whereas the 10 mg DXR vials were packaged as 10 vials in one cardboard box. The same lot of each product was used in the study. In addition, none of the vials were covered with additional materials such as plastic. Fluorescein sodium salt was obtained from Sigma-Aldrich Japan Co LLC (Tokyo, Japan). 
Chemicals
Wipe sampling of drug vials
Preparation of the sample solutions for HPLC
The sample solutions were prepared from the non-woven fabric, as described previously. 8 
HPLC-Fluorescence analysis
Results
Evaluation of analysis for DXR
Retention times of DXR and uorescein (inter-nal standard) were 3.6 and 5.4 minutes, respectively ( Fig. 1) . We first estimated analysis for 
Evaluation of wiping of the external surfaces of drug vials
Before analysing external contamination level of vials, we performed wiping test for this study.
We dropped DXR solution (2-propanol) on glass plates and dried it within a radius of 5 cm to add 5 ng and 10 ng DXR on the glass plates (n = 3).
Then, we wiped the divisions on the glass plates, and evaluated recovery of DXR.
Ninety four percent and 83％ of 5 ng and 10 ng 
Contamination level on the external surfaces of drug vials
We analyzed 57 vials of six products containing 10 or 50 mg of the material from three Japanese pharmaceutical companies by HPLC-FL and found 28 vials that were contaminated with DXR ( Fig. 1, Table 1 ). Before wipe sampling, the cardboard boxes and outer sides of drug vials were visually inspected to detect contamination by breakage or leakage; no sign of damage was detected.
We compared the surface contamination on two vials sizes from the same company. The 10 mg vials were highly contaminated as compared with 50 mg vials. We also wiped the surfaces of vials containing another lot of Product No. 5. The results from the two lots of Product No. 5 are presented in Table 2 , which revealed that the contamination levels were different between the lots even though the manufacturing process was same.
Confirmation of DXR with LC-TOF MS
The Furthermore, fragmentation of the DXR ion has been shown to produce prominent fragments of m/z 397.0931. 10) We also observed a peak at m/z 397.09 in EICs of the DXR standard preparation and the wipe sample. As expected, the retention times were the same (Fig. 2B) .
Because the accurate mass, retention time and fragment ion of the wipe sample corresponded with those of the DXR standard preparation, the contaminant in the wipe samples was con rmed to be DXR. 
Discussion
This study revealed that there was DXR contamination on the external surfaces of drug vials produced and collected in Japan. We speculate that the external contamination originated from the manufacture or packaging process at the pharmaceutical companies because there were no breakage and leakage on the cardboard boxes and outer sides of drug vials.
In this study, we investigated the external con- urine of a pharmacist who had not prepared antineoplastic drugs but had collected the drug vials. 9) It was considered that there was the possibility of occupational exposure derived from the external surface of vials. However, the hazard of the external contamination has not known widely in Japan.
One of the reasons of that was considered that 
11)
In this study, we validated that the previously reported method 8) 
